Adults with early type two diabetes and elevated cardiovascular risk may be able to safely take linagliptin or sulfonylurea (glimepiride) without increasing their risk of cardiovascular events, researchers report in JAMA.
Among adults with recently-diagnosed type 2 diabetes and elevated cardiovascular risk, the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin and the sulfonylurea glimepiride treatment resulted in similar cardiovascular outcomes over a median 6.3 years.
Authors of a new study found that patients who develop diabetes later in life have a higher risk of cardiovascular disease.
Is the number of CV health measures associated with similar risk reduction among patients with higher T2DM risk or lower risk? New study sheds light.